Posted in | News | Gold | Mining Business

Endeavour Sells Major Portion of its Non-Core Agbaou Mine to Allied Gold Corp

Endeavour Mining reports that it has signed an agreement to sell its 85% interest in its non-core Agbaou mine in Côte d’Ivoire to Allied Gold Corp.

The sale will be for a consideration of up to $80 million with additional benefits via a Net Smelter Return (NSR) royalty and its equity exposure.

The sale of our interest in the Agbaou mine to Allied Gold is in line with our strategy of actively managing our portfolio to focus management efforts on high margin, long-life core assets.

Sébastien de Montessus, President and CEO, Endeavour Mining Corporation

Montessus continued, “Agbaou has been a highly cash generative asset which facilitated the organic development of Houndé and Ity, and given that it has now become non-core to Endeavour, we firmly believe that this transaction is in the best interests of all of Agbaou’s stakeholders, including the Government of Cote d’Ivoire, local communities and the employees themselves. This transaction will ensure mining activities can continue for many years to come through the creation of the Bonikro-Agbaou complex.”

We are very proud of what we have accomplished at Agbaou as we have installed a strong and capable team, which is now led by an Ivorian General Manager, supported by a number of local employees in leadership positions, ensuring we leave behind a strong legacy. I want to thank our Agbaou employees for their huge commitment, professionalism and contribution to Endeavour’s evolution over the past years,” added Montessus.

Allied Gold is a private African operator that significantly owns the Bonikro mine in the vicinity. As soon as the transaction is sealed, the Bonikro-Agbaou operation will include several open pits, two processing plants including a total milling capacity of more than 5 Mtpa, and will have the capacity to generate more than 285,000 ounces per year.

Endeavour anticipates that it can acquire the advantages of local synergies and exploration benefits via its NSR royalty and equity stake in Allied Gold.

Listed below are the terms and conditions of the agreement included in the entire consideration:

  • $20 million in cash should be paid in Q1 of 2021
  • $40 million in Allied Gold shares. Endeavour has a choice to sell back the shares to Allied Gold at the issue price, expiring on December 31st, 2022, or earlier if Allied Gold performs an IPO earlier
  • A contingent payment of nearly $20 million, inclusive of $5 million for each quarter of 2021 where the average gold cost goes beyond $1,900/oz
  • An NSR royalty that has been generated on ounces surplus of the Agbaou reserves approximated as of December 31st, 2019. The NSR royalty will be dependent on a sliding scale, that is associated with the average spot gold cost as follows: 2.5% if the gold cost is at a minimum of $1,400/oz, 2% if the gold cost is at least $1,200/oz and less than $1,400/oz, 1% if the gold cost is at least $1,000/oz and less than $1,200/oz, and 0% if the gold cost is below $1,000/oz.

The transaction is anticipated to close on March 1st, 2021.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Azthena logo powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.